Experimental and Molecular Medicine (Feb 2020)

New role of the antidepressant imipramine as a Fascin1 inhibitor in colorectal cancer cells

  • Begoña Alburquerque-González,
  • Manuel Bernabé-García,
  • Silvia Montoro-García,
  • Ángel Bernabé-García,
  • Priscila Campioni Rodrigues,
  • Javier Ruiz Sanz,
  • Fernando F. López-Calderón,
  • Irene Luque,
  • Francisco José Nicolas,
  • María Luisa Cayuela,
  • Tuula Salo,
  • Horacio Pérez-Sánchez,
  • Pablo Conesa-Zamora

DOI
https://doi.org/10.1038/s12276-020-0389-x
Journal volume & issue
Vol. 52, no. 2
pp. 281 – 292

Abstract

Read online

Colorectal cancer: Antitumor antidepressant The antidepressant drug imipramine can block the activity of a protein that contributes to the progression of certain aggressive tumors. Serrated adenocarcinoma (SAC) is a form of colorectal cancer with a poor prognosis. A key factor in SAC development is the overexpression of the protein fascin1, which promotes the formation of structures that help cancer cells move around, thereby leading to metastasis. Pablo Conesa-Zamora at Santa Lucia University Hospital in Cartagena, Horacio Pérez-Sánchez at the Universidad Católica de Murcia in Guadalupe, Spain, and coworkers demonstrated that imipramine shows promise in binding to fascin1 and blocking its activity. The team analyzed over 9500 compounds as potential fascin1 blockers, identifying imipramine as a possible option. In tests on human tissues and in vivo studies using zebrafish, the drug reduced cancer invasion and metastasis.